ÂÜÀòÂÒÂ×

Charles Morris. MBChB, MRCP, is a medical oncologist with over 25 years of oncology drug development experience in the international biotech and pharmaceutical industry. Most recently, Dr. Morris was chief medical officer for Celyad Oncology, a CAR-T focused cell therapy company. In other CMO roles with Radius Health, PsiOxus Therapeutics, ImmunoGen and Allos Therapeutics, he contributed to all phases of development for several novel programs targeting solid and hematological tumor indications. He served as vice president of worldwide clinical research at Cephalon where he supported the approval of TREANDA® (bendamustine) for the treatment of indolent non-Hodgkin lymphoma and chronic lymphocytopenia. Dr. Morris began his career at AstraZeneca where he held roles of increasing responsibility including global medical lead for Faslodex® (fulvestrant) through its approval for breast cancer. He received a Bachelor of Medicine, Bachelor of Surgery and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics degree from Sheffield University Medical School and is a Member of the Royal College of Physicians of London.